MorphoSys to Give Company Presentations at Five Investor Conferences
in the US and Europe
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that its management will give company presentations at five
investor conferences in September 2008.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will
present an overview of the Company at the following conferences:
Sal. Oppenheim's 3rd European Healthcare Investors Conference
Date: Wednesday, September 3, 2008
Time: 12.20 pm CET (11.20 am BST / 06.20 am EDT)
Venue: Villa Kennedy, Frankfurt/Main, Germany
Newsmakers in the Biotech Industry Conference
Date: Thursday, September 4, 2008
Time: 09.30 am EDT (03.30 pm CET / 02.30 pm BST)
Venue: Millennium Broadway Hotel, New York City, USA
Danske Markets Equities' and ESN's Antibody Seminar
Date: Tuesday, September 30, 2008
Venue: Danske Bank, Stockholm, Sweden
Dave Lemus, Chief Financial Officer of MorphoSys AG, will present an
overview of the Company at the following conferences:
2nd Goldman Sachs Biotech Symposium
Date: Friday, September 5, 2008
Venue: Goldman Sachs, London, UK
8th Annual Biotech in Europe Investor Forum
Date: Tuesday, September 23, 2008
Venue: Swissôtel, Zurich, Switzerland
"Our invitation to the Newsmakers conference in New York illustrates
the increasing investor interest in MorphoSys", commented Dr. Claudia
Gutjahr-Löser, Head of Corporate Communications & Investor Relations
of MorphoSys AG.
Live and archived webcasts of the presentations will be available at
www.morphosys.com.
For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj,
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/
HuCAL(R), HuCAL GOLD(R) and RapMAT(R) are registered trademarks of
MorphoSys AG
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.
